ALT-803 + gemcitabine + nab-paclitaxel

ALT-803 + gemcitabine + nab-paclitaxel is an **investigational combination regimen** for cancer therapy, consisting of: - **ALT-803 (N-803)**: a novel interleukin-15 (IL-15)-based immunostimulatory superagonist complex that markedly activates and proliferates CD8+ T cells and natural killer (NK) cells, enhancing both innate and adaptive anti-tumor immunity. ALT-803 contains a mutant IL-15 (IL-15N72D) with enhanced affinity for the IL-2 receptor β chain, bound to a dimeric IL-15 receptor alpha-IgG Fc fusion protein, resulting in much greater stability and in vivo potency than native IL-15. - **Gemcitabine**: a standard chemotherapy drug classified as a nucleoside analog antimetabolite, interfering with DNA synthesis and used in a variety of malignancies. - **Nab-paclitaxel**: an albumin-bound nanoparticle formulation of paclitaxel, a microtubule inhibitor, facilitating cytotoxic activity against dividing cancer cells. This combination is being explored particularly in settings such as pancreatic cancer and other solid tumors, leveraging the immunostimulatory properties of ALT-803 alongside cytotoxic agents to potentially enhance anti-tumor efficacy[1][3].

Other names

N-803 + gemcitabine + nab-paclitaxelIL-15 superagonist complex + gemcitabine + nab-paclitaxelIL-15N72D complex + gemcitabine + nab-paclitaxel